Beyond the Coronaries: MK-7, Plaque Calcification, and the Systemic Logic of Atherosclerosis

A new randomized clinical trial in JAMA Cardiology reported that two years of menaquinone-7, or MK-7, may slow calcification in noncalcified plaques among patients with symptomatic coronary artery disease. The authors were appropriately cautious: the clinical significance of this finding for plaque stability remains uncertain. Yet the study raises a larger question that should not be confined too narrowly to the coronary arteries alone. If atherosclerosis is truly a systemic disease, why should we think about this result only in coronary terms? 

That question is not rhetorical. It goes to the conceptual core of atherosclerosis. As argued in our Atherosclerosis: Bridging Genetics, Inflammation, and Clinical Realities, atherosclerosis is not merely a local lesion of one favored vascular territory but a chronic systemic inflammatory disease expressed in different arterial beds according to local conditions, timing, and clinical visibility. Coronary, carotid, femoral, aortic, and peripheral plaques are not separate diseases. They are regional manifestations of one systemic process. 

This is exactly why the traditional habit of reasoning from one vascular bed to another is not a mistake but often a necessity. In this book, the discussion of femoral, carotid, and coronary disease emphasizes that when atherosclerosis is discovered in one territory, clinicians should assume broader systemic involvement and evaluate the patient accordingly. The 2002 European Society of Cardiology perspective cited there showed that peripheral arterial disease often coexists with coronary and carotid disease, reinforcing that visible disease in one bed is a marker for hidden disease elsewhere. By the same logic, a biological effect on plaque calcification in coronary arteries invites us to consider whether a similar effect may exist in other arterial territories. 

The principle of symmetry gives this argument its philosophical and clinical shape. If the same systemic metabolic, inflammatory, and calcific forces operate across the arterial tree, then a therapy influencing one expression of that process may reasonably be expected to influence analogous lesions elsewhere, unless evidence shows otherwise. This does not mean that every artery behaves identically. Hemodynamics, wall structure, plaque composition, and clinical consequences vary from one vascular territory to another. But the underlying disease process remains shared, and that shared process is precisely what gives systemic interpretation its legitimacy. 

There is also a biologic rationale for why MK-7 might matter beyond the coronaries. The proposed mechanism centers on vitamin K-dependent activation of matrix Gla protein, an inhibitor of vascular calcification produced by vascular smooth muscle cells. If that mechanism is real, it is not coronary-specific in principle. Vascular smooth muscle cells and calcification biology are not exclusive to the coronary circulation. That makes it reasonable to view the coronary finding as a window into a more general arterial phenomenon, even if direct proof in carotid, femoral, or other beds is still lacking. 

Still, scientific discipline matters. The JAMA trial does not prove that MK-7 stabilizes plaques, reduces stroke, prevents limb ischemia, or slows calcification in every artery. It shows a modest imaging effect in coronary disease, while the accompanying editorial underscores that whether slowing early calcification improves clinical outcomes remains unknown. So the right conclusion is not careless generalization, but careful expansion: coronary evidence should stimulate a systemic hypothesis, not terminate inquiry. 

That, in fact, is the broader lesson. Atherosclerosis should be studied and treated as one disease with many local faces. When meaningful findings emerge in one vascular bed, we should neither imprison them there nor overstate them beyond the evidence. We should interpret them through the systemic nature of atherosclerosis, the principle of symmetry, and the obligation to think beyond organ silos. In that sense, the MK-7 study is not only about coronary calcium. It is about whether modern vascular medicine is finally ready to think as systemically as the disease itself.

You can learn more by reading our e-book or listening to our audiobook

Mykola Iabluchanskyi (Yabluchansky) together with Andriy Yabluchanskiy